Monument Therapeutics Secures £1M Investment to Fund Its Schizophrenia Programme And Drive Next Stage of Growth
Monument Therapeutics, a precision neuroscience company, today announced a further £1M equity investment by the Forster Foundation, a charitable incorporated organisation.
Qkine wins ‘Scale-up of the Year’ at the 2024 Cambridge Independent Business Awards
On the 26th September 2024, Qkine representatives Catherine Elton, CEO and Luana Ferrara, Head of R&D and Collaborations joined some of the most impressive Cambridge business leaders for an exciting evening of networking and entertainment at the Cambridge Independent Business awards ceremony held in the spectacular Great Hall at King’s College, Cambridge.
NK:IO progresses ovarian cancer natural killer therapy
Imperial College spin-out company NK:IO has completed a seed round to a total of £5.9 ($7.8) million.
‘We’re building the UK’s first $1tn company’ — Amazon Alexa creator’s new startup
William Tunstall-Pedoe sold his startup Evi to Amazon, paving the way for Alexa — but has no plans to sell his new startup to US Big Tech
£11.5m to improve semiconductor manufacturing and supply chains
Innovate UK, part of UK Research and Innovation, has invested £11.5 million across 16 projects to improve and scale-up semiconductor manufacturing and supply chains.
Oxford drug design secures funding to combat cystic fibrosis lung infections
£3m programme to accelerate new antimicrobial treatment
Rovco and Vaarst’s new brand makes €17.8M investment in its fleet
Beam, a new brand formed by the merger of UK-based providers of tech-powered offshore wind solutions Rovco and Vaarst, has added two autonomous surface vessels (ASVs) and an electric work-class remotely operated vehicle (ROV) to its fleet.
New director unveiled at Sphere Fluidics as company eyes US expansion
Sphere Fluidics, a Cambridge-based provider of innovative microfluidics-based solutions for single-cell analysis and isolation, has appointed a new non-executive director to its board of directors.
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes
Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER™ platform
Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Amadeus Capital and Astellas Venture Management
CardiaTec Secures $6.5M Seed Funding to Advance Its Multi-omics Drug Discovery Platform for Cardiovascular Diseases
CardiaTec, a TechBio company employing computational methods to decode the biology behind cardiovascular disease, has raised $6.5M in seed funding led by San Francisco-based Montage Ventures.
Qkine expands senior leadership with the appointment of Rob Nixon, Commercial Director, and Paul Grafham, Chief Financial Officer
Qkine is delighted to announce the appointment of Rob Nixon to its leadership team as Commercial Director and Paul Grafham as Chief Financial Officer. With years of experience working with fast-growing biotechs and life science reagent suppliers, these appointments will support the execution of the company’s growth strategies and expansion of its commercial operations globally.
Paragraf Looks Toward Scaling Up Production of Graphene Devices
Graphene has long been touted as a wonder material that could transform electronics, thanks to its superior electrical and thermal conductivity. One company that has been on a mission to spur adoption of graphene-based devices and scale up production is Paragraf.
VividQ opening US office after taking funding haul past $30m
Cambridge DeepTech innovator VividQ is expanding in the United States on the wings of fresh funding success. VividQ, a leader in computational holography, has secured an extra $7.5 million Series A funding, bringing its total haul to more than $30m.
Abselion announces £1.1m project to develop next-gen cell platform for viral vector production
Biotechnology companies and research organisations in the UK and Canada are entering into a R&D project jointly funded by a 1.1 million GBP grant from Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project is led by VVector Bio and joined by the NRC, Revvity and Abselion.
Hughes Hall honours Chausiaux as Heartfelt Technologies eyes global expansion
Cambridge University college Hughes Hall has honoured alumna Dr Oriane Chausiaux for being awarded the Women in Innovation Award by Innovate UK.
Rovco joins Global Wind Energy Council
Rovco, a leader in tech-driven offshore wind solutions, has joined global industry group the Global Wind Energy Council (GWEC). In joining GWEC, Rovco becomes part of a leading community of more than 1,500 companies across 80 countries, collaborating to create a better global policy environment for wind power.
AI projects backed by £32 million to turbocharge productivity
Almost 100 new projects will use artificial intelligence (AI) to improve productivity across the economy.
Cambridge drug discovery startup Healx raises £37m
Cambridge-based drug discovery startup Healx has announced a $47m (£37m) Series C funding round as its trial neurofibromatosis treatment receives regulatory approval.
What Library of Things has taught us about behaviour change
Co-Founder of Library of Things Rebecca Trevalyan explains what the company has taught her about how and why people change their behaviour.
Interview with Rovco CEO: New technologies can close huge offshore wind skills gap
New technologies have the ability to massively close the huge skills gap and shortage of workers that is looming over the offshore wind industry, allowing 10 to 17 times more work to be done by one person, according to Brian Allen, CEO of Rovco, a UK company focused on automating offshore wind services by creating and deploying novel tech solutions.